ptc124 targets genetic disorders caused nonsense mutations
nonsense mutations promote premature translational termination cause anywhere % individual cases inherited diseases studies nonsense-mediated cystic fibrosis indicated boosting specific protein synthesis < % little % normal levels may greatly reduce severity eliminate principal manifestations disease address need drug capable suppressing premature termination identified ptc124 new chemical entity selectively induces ribosomal readthrough premature normal termination codons ptc124 activity optimized using nonsense-containing reporters promoted dystrophin production primary muscle cells humans mdx mice expressing dystrophin nonsense alleles rescued striated muscle function mdx mice within weeks drug exposure ptc124 well tolerated animals plasma exposures substantially excess required nonsense suppression selectivity ptc124 premature termination codons well characterized activity profile oral bioavailability pharmacological properties indicate drug may broad clinical potential treatment large group genetic disorders limited therapeutic options
